nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadopentetate dimeglumine—Gadobenate Dimeglumine—ALB—liver cancer	0.0152	1	CrCbGaD
Gadopentetate dimeglumine—PGD—NRF2 pathway—DNAJB1—liver cancer	0.00946	0.0984	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—NRF2 pathway—GSTA3—liver cancer	0.00543	0.0565	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—NRF2 pathway—GSTA4—liver cancer	0.00497	0.0517	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—NRF2 pathway—GSTA2—liver cancer	0.00484	0.0504	CbGpPWpGaD
Gadopentetate dimeglumine—Urethral disorder—Sorafenib—liver cancer	0.00473	0.00533	CcSEcCtD
Gadopentetate dimeglumine—Burning sensation—Doxorubicin—liver cancer	0.00473	0.00532	CcSEcCtD
Gadopentetate dimeglumine—Scotoma—Epirubicin—liver cancer	0.00468	0.00526	CcSEcCtD
Gadopentetate dimeglumine—PGD—NRF2 pathway—GSTA1—liver cancer	0.00467	0.0486	CbGpPWpGaD
Gadopentetate dimeglumine—Nystagmus—Doxorubicin—liver cancer	0.0046	0.00518	CcSEcCtD
Gadopentetate dimeglumine—Erythema multiforme—Sorafenib—liver cancer	0.00456	0.00514	CcSEcCtD
Gadopentetate dimeglumine—Feeling hot—Epirubicin—liver cancer	0.00453	0.00509	CcSEcCtD
Gadopentetate dimeglumine—Tinnitus—Sorafenib—liver cancer	0.0045	0.00507	CcSEcCtD
Gadopentetate dimeglumine—Flushing—Sorafenib—liver cancer	0.00448	0.00504	CcSEcCtD
Gadopentetate dimeglumine—Cardiac disorder—Sorafenib—liver cancer	0.00448	0.00504	CcSEcCtD
Gadopentetate dimeglumine—Rash pustular—Epirubicin—liver cancer	0.00445	0.00501	CcSEcCtD
Gadopentetate dimeglumine—Angiopathy—Sorafenib—liver cancer	0.00438	0.00493	CcSEcCtD
Gadopentetate dimeglumine—Immune system disorder—Sorafenib—liver cancer	0.00436	0.00491	CcSEcCtD
Gadopentetate dimeglumine—Injection site pain—Epirubicin—liver cancer	0.00435	0.0049	CcSEcCtD
Gadopentetate dimeglumine—Mediastinal disorder—Sorafenib—liver cancer	0.00435	0.0049	CcSEcCtD
Gadopentetate dimeglumine—Scotoma—Doxorubicin—liver cancer	0.00433	0.00487	CcSEcCtD
Gadopentetate dimeglumine—Arrhythmia—Sorafenib—liver cancer	0.00431	0.00485	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Sorafenib—liver cancer	0.00423	0.00476	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Sorafenib—liver cancer	0.0042	0.00473	CcSEcCtD
Gadopentetate dimeglumine—Feeling hot—Doxorubicin—liver cancer	0.00419	0.00471	CcSEcCtD
Gadopentetate dimeglumine—Rash pustular—Doxorubicin—liver cancer	0.00412	0.00464	CcSEcCtD
Gadopentetate dimeglumine—PGD—NRF2 pathway—NFE2L2—liver cancer	0.00412	0.0428	CbGpPWpGaD
Gadopentetate dimeglumine—Dysgeusia—Sorafenib—liver cancer	0.00412	0.00463	CcSEcCtD
Gadopentetate dimeglumine—Vasodilation procedure—Epirubicin—liver cancer	0.00404	0.00455	CcSEcCtD
Gadopentetate dimeglumine—Vasodilation—Epirubicin—liver cancer	0.00404	0.00455	CcSEcCtD
Gadopentetate dimeglumine—Injection site pain—Doxorubicin—liver cancer	0.00403	0.00453	CcSEcCtD
Gadopentetate dimeglumine—PGD—NRF2 pathway—GPX3—liver cancer	0.00393	0.0409	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—NRF2 pathway—TGFA—liver cancer	0.00393	0.0409	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—NRF2 pathway—SERPINA1—liver cancer	0.00387	0.0403	CbGpPWpGaD
Gadopentetate dimeglumine—Lacrimation increased—Epirubicin—liver cancer	0.00386	0.00434	CcSEcCtD
Gadopentetate dimeglumine—Angioedema—Sorafenib—liver cancer	0.00384	0.00432	CcSEcCtD
Gadopentetate dimeglumine—Syncope—Sorafenib—liver cancer	0.00377	0.00424	CcSEcCtD
Gadopentetate dimeglumine—Blood bilirubin increased—Epirubicin—liver cancer	0.00376	0.00423	CcSEcCtD
Gadopentetate dimeglumine—Vasodilation procedure—Doxorubicin—liver cancer	0.00374	0.00421	CcSEcCtD
Gadopentetate dimeglumine—Vasodilation—Doxorubicin—liver cancer	0.00374	0.00421	CcSEcCtD
Gadopentetate dimeglumine—Loss of consciousness—Sorafenib—liver cancer	0.00369	0.00416	CcSEcCtD
Gadopentetate dimeglumine—Cough—Sorafenib—liver cancer	0.00367	0.00413	CcSEcCtD
Gadopentetate dimeglumine—Hypertension—Sorafenib—liver cancer	0.00363	0.00408	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Sorafenib—liver cancer	0.00358	0.00403	CcSEcCtD
Gadopentetate dimeglumine—Lacrimation increased—Doxorubicin—liver cancer	0.00357	0.00401	CcSEcCtD
Gadopentetate dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00355	0.004	CcSEcCtD
Gadopentetate dimeglumine—Injection site reaction—Epirubicin—liver cancer	0.00353	0.00397	CcSEcCtD
Gadopentetate dimeglumine—Dry mouth—Sorafenib—liver cancer	0.0035	0.00394	CcSEcCtD
Gadopentetate dimeglumine—Blood bilirubin increased—Doxorubicin—liver cancer	0.00348	0.00391	CcSEcCtD
Gadopentetate dimeglumine—Salivary hypersecretion—Epirubicin—liver cancer	0.00345	0.00388	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Sorafenib—liver cancer	0.00343	0.00386	CcSEcCtD
Gadopentetate dimeglumine—Shock—Sorafenib—liver cancer	0.00337	0.0038	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Sorafenib—liver cancer	0.00336	0.00378	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Sorafenib—liver cancer	0.00333	0.00375	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Sorafenib—liver cancer	0.00327	0.00368	CcSEcCtD
Gadopentetate dimeglumine—Injection site reaction—Doxorubicin—liver cancer	0.00327	0.00368	CcSEcCtD
Gadopentetate dimeglumine—Coma—Epirubicin—liver cancer	0.00325	0.00365	CcSEcCtD
Gadopentetate dimeglumine—Salivary hypersecretion—Doxorubicin—liver cancer	0.00319	0.00359	CcSEcCtD
Gadopentetate dimeglumine—Pulmonary oedema—Epirubicin—liver cancer	0.00316	0.00356	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00312	0.00352	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Sorafenib—liver cancer	0.00306	0.00344	CcSEcCtD
Gadopentetate dimeglumine—Coma—Doxorubicin—liver cancer	0.003	0.00338	CcSEcCtD
Gadopentetate dimeglumine—Phlebitis—Epirubicin—liver cancer	0.00299	0.00337	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Sorafenib—liver cancer	0.00298	0.00336	CcSEcCtD
Gadopentetate dimeglumine—Thrombophlebitis—Epirubicin—liver cancer	0.00298	0.00335	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Sorafenib—liver cancer	0.00296	0.00333	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Sorafenib—liver cancer	0.00296	0.00333	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Sorafenib—liver cancer	0.00293	0.0033	CcSEcCtD
Gadopentetate dimeglumine—Pain—Sorafenib—liver cancer	0.00293	0.0033	CcSEcCtD
Gadopentetate dimeglumine—Pulmonary oedema—Doxorubicin—liver cancer	0.00293	0.00329	CcSEcCtD
Gadopentetate dimeglumine—Eye pain—Epirubicin—liver cancer	0.00286	0.00321	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Sorafenib—liver cancer	0.0028	0.00316	CcSEcCtD
Gadopentetate dimeglumine—PGD—Carbohydrate metabolism—ALDOB—liver cancer	0.0028	0.0291	CbGpPWpGaD
Gadopentetate dimeglumine—Renal failure acute—Epirubicin—liver cancer	0.00279	0.00314	CcSEcCtD
Gadopentetate dimeglumine—Phlebitis—Doxorubicin—liver cancer	0.00277	0.00312	CcSEcCtD
Gadopentetate dimeglumine—PGD—NRF2 pathway—GGT1—liver cancer	0.00276	0.0288	CbGpPWpGaD
Gadopentetate dimeglumine—Thrombophlebitis—Doxorubicin—liver cancer	0.00276	0.0031	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Sorafenib—liver cancer	0.00272	0.00307	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Sorafenib—liver cancer	0.00271	0.00305	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Sorafenib—liver cancer	0.00271	0.00305	CcSEcCtD
Gadopentetate dimeglumine—Renal impairment—Epirubicin—liver cancer	0.00271	0.00305	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactoid reaction—Epirubicin—liver cancer	0.00266	0.003	CcSEcCtD
Gadopentetate dimeglumine—Eye pain—Doxorubicin—liver cancer	0.00264	0.00297	CcSEcCtD
Gadopentetate dimeglumine—PGD—Disease—APCS—liver cancer	0.00263	0.0274	CbGpPWpGaD
Gadopentetate dimeglumine—Renal failure acute—Doxorubicin—liver cancer	0.00258	0.00291	CcSEcCtD
Gadopentetate dimeglumine—Diplopia—Epirubicin—liver cancer	0.00258	0.0029	CcSEcCtD
Gadopentetate dimeglumine—Pain in extremity—Epirubicin—liver cancer	0.00258	0.0029	CcSEcCtD
Gadopentetate dimeglumine—Migraine—Epirubicin—liver cancer	0.00254	0.00286	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Sorafenib—liver cancer	0.00253	0.00284	CcSEcCtD
Gadopentetate dimeglumine—Renal impairment—Doxorubicin—liver cancer	0.00251	0.00282	CcSEcCtD
Gadopentetate dimeglumine—Face oedema—Epirubicin—liver cancer	0.00249	0.0028	CcSEcCtD
Gadopentetate dimeglumine—PGD—NRF2 pathway—GSTP1—liver cancer	0.00248	0.0258	CbGpPWpGaD
Gadopentetate dimeglumine—Anaphylactoid reaction—Doxorubicin—liver cancer	0.00247	0.00277	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Sorafenib—liver cancer	0.00246	0.00277	CcSEcCtD
Gadopentetate dimeglumine—Cardiac arrest—Epirubicin—liver cancer	0.00245	0.00276	CcSEcCtD
Gadopentetate dimeglumine—PGD—NRF2 pathway—HMOX1—liver cancer	0.00245	0.0255	CbGpPWpGaD
Gadopentetate dimeglumine—Pruritus—Sorafenib—liver cancer	0.00243	0.00273	CcSEcCtD
Gadopentetate dimeglumine—Blood creatinine increased—Epirubicin—liver cancer	0.00242	0.00272	CcSEcCtD
Gadopentetate dimeglumine—Diplopia—Doxorubicin—liver cancer	0.00239	0.00269	CcSEcCtD
Gadopentetate dimeglumine—Pain in extremity—Doxorubicin—liver cancer	0.00239	0.00269	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain upper—Epirubicin—liver cancer	0.00236	0.00265	CcSEcCtD
Gadopentetate dimeglumine—Migraine—Doxorubicin—liver cancer	0.00235	0.00264	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Sorafenib—liver cancer	0.00235	0.00264	CcSEcCtD
Gadopentetate dimeglumine—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00232	0.00261	CcSEcCtD
Gadopentetate dimeglumine—Nasopharyngitis—Epirubicin—liver cancer	0.00231	0.0026	CcSEcCtD
Gadopentetate dimeglumine—Face oedema—Doxorubicin—liver cancer	0.0023	0.00259	CcSEcCtD
Gadopentetate dimeglumine—PGD—NRF2 pathway—GSTM1—liver cancer	0.00228	0.0237	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—NRF2 pathway—HGF—liver cancer	0.00228	0.0237	CbGpPWpGaD
Gadopentetate dimeglumine—Cardiac arrest—Doxorubicin—liver cancer	0.00227	0.00255	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Sorafenib—liver cancer	0.00227	0.00255	CcSEcCtD
Gadopentetate dimeglumine—Blood creatinine increased—Doxorubicin—liver cancer	0.00224	0.00252	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Sorafenib—liver cancer	0.00218	0.00245	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain upper—Doxorubicin—liver cancer	0.00218	0.00245	CcSEcCtD
Gadopentetate dimeglumine—Angina pectoris—Epirubicin—liver cancer	0.00217	0.00244	CcSEcCtD
Gadopentetate dimeglumine—Rash—Sorafenib—liver cancer	0.00216	0.00243	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Sorafenib—liver cancer	0.00216	0.00243	CcSEcCtD
Gadopentetate dimeglumine—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00215	0.00242	CcSEcCtD
Gadopentetate dimeglumine—Headache—Sorafenib—liver cancer	0.00215	0.00242	CcSEcCtD
Gadopentetate dimeglumine—Nasopharyngitis—Doxorubicin—liver cancer	0.00213	0.0024	CcSEcCtD
Gadopentetate dimeglumine—Pollakiuria—Epirubicin—liver cancer	0.00206	0.00232	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Sorafenib—liver cancer	0.00204	0.00229	CcSEcCtD
Gadopentetate dimeglumine—PGD—Carbohydrate metabolism—GOT2—liver cancer	0.00202	0.0211	CbGpPWpGaD
Gadopentetate dimeglumine—Angina pectoris—Doxorubicin—liver cancer	0.00201	0.00226	CcSEcCtD
Gadopentetate dimeglumine—Drowsiness—Epirubicin—liver cancer	0.00199	0.00224	CcSEcCtD
Gadopentetate dimeglumine—Renal failure—Epirubicin—liver cancer	0.00195	0.0022	CcSEcCtD
Gadopentetate dimeglumine—Conjunctivitis—Epirubicin—liver cancer	0.00193	0.00217	CcSEcCtD
Gadopentetate dimeglumine—Sweating—Epirubicin—liver cancer	0.00191	0.00214	CcSEcCtD
Gadopentetate dimeglumine—Pollakiuria—Doxorubicin—liver cancer	0.00191	0.00214	CcSEcCtD
Gadopentetate dimeglumine—Hepatobiliary disease—Epirubicin—liver cancer	0.00188	0.00212	CcSEcCtD
Gadopentetate dimeglumine—Drowsiness—Doxorubicin—liver cancer	0.00184	0.00207	CcSEcCtD
Gadopentetate dimeglumine—Bradycardia—Epirubicin—liver cancer	0.00182	0.00204	CcSEcCtD
Gadopentetate dimeglumine—Renal failure—Doxorubicin—liver cancer	0.00181	0.00203	CcSEcCtD
Gadopentetate dimeglumine—Rhinitis—Epirubicin—liver cancer	0.00179	0.00201	CcSEcCtD
Gadopentetate dimeglumine—Conjunctivitis—Doxorubicin—liver cancer	0.00179	0.00201	CcSEcCtD
Gadopentetate dimeglumine—Sweating—Doxorubicin—liver cancer	0.00176	0.00198	CcSEcCtD
Gadopentetate dimeglumine—Urinary tract disorder—Epirubicin—liver cancer	0.00176	0.00198	CcSEcCtD
Gadopentetate dimeglumine—Oedema peripheral—Epirubicin—liver cancer	0.00176	0.00198	CcSEcCtD
Gadopentetate dimeglumine—Connective tissue disorder—Epirubicin—liver cancer	0.00175	0.00197	CcSEcCtD
Gadopentetate dimeglumine—Urethral disorder—Epirubicin—liver cancer	0.00175	0.00197	CcSEcCtD
Gadopentetate dimeglumine—PGD—Carbohydrate metabolism—GOT1—liver cancer	0.00175	0.0182	CbGpPWpGaD
Gadopentetate dimeglumine—Hepatobiliary disease—Doxorubicin—liver cancer	0.00174	0.00196	CcSEcCtD
Gadopentetate dimeglumine—Visual impairment—Epirubicin—liver cancer	0.00172	0.00193	CcSEcCtD
Gadopentetate dimeglumine—Erythema multiforme—Epirubicin—liver cancer	0.00169	0.0019	CcSEcCtD
Gadopentetate dimeglumine—Bradycardia—Doxorubicin—liver cancer	0.00168	0.00189	CcSEcCtD
Gadopentetate dimeglumine—Eye disorder—Epirubicin—liver cancer	0.00167	0.00188	CcSEcCtD
Gadopentetate dimeglumine—Tinnitus—Epirubicin—liver cancer	0.00166	0.00187	CcSEcCtD
Gadopentetate dimeglumine—Cardiac disorder—Epirubicin—liver cancer	0.00166	0.00186	CcSEcCtD
Gadopentetate dimeglumine—Flushing—Epirubicin—liver cancer	0.00166	0.00186	CcSEcCtD
Gadopentetate dimeglumine—Rhinitis—Doxorubicin—liver cancer	0.00166	0.00186	CcSEcCtD
Gadopentetate dimeglumine—Urinary tract disorder—Doxorubicin—liver cancer	0.00163	0.00183	CcSEcCtD
Gadopentetate dimeglumine—Oedema peripheral—Doxorubicin—liver cancer	0.00163	0.00183	CcSEcCtD
Gadopentetate dimeglumine—Connective tissue disorder—Doxorubicin—liver cancer	0.00162	0.00183	CcSEcCtD
Gadopentetate dimeglumine—Angiopathy—Epirubicin—liver cancer	0.00162	0.00182	CcSEcCtD
Gadopentetate dimeglumine—Urethral disorder—Doxorubicin—liver cancer	0.00162	0.00182	CcSEcCtD
Gadopentetate dimeglumine—Immune system disorder—Epirubicin—liver cancer	0.00161	0.00181	CcSEcCtD
Gadopentetate dimeglumine—Mediastinal disorder—Epirubicin—liver cancer	0.00161	0.00181	CcSEcCtD
Gadopentetate dimeglumine—Chills—Epirubicin—liver cancer	0.0016	0.0018	CcSEcCtD
Gadopentetate dimeglumine—Arrhythmia—Epirubicin—liver cancer	0.00159	0.00179	CcSEcCtD
Gadopentetate dimeglumine—Visual impairment—Doxorubicin—liver cancer	0.00159	0.00179	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Epirubicin—liver cancer	0.00156	0.00176	CcSEcCtD
Gadopentetate dimeglumine—Erythema multiforme—Doxorubicin—liver cancer	0.00156	0.00176	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Epirubicin—liver cancer	0.00155	0.00175	CcSEcCtD
Gadopentetate dimeglumine—Eye disorder—Doxorubicin—liver cancer	0.00154	0.00174	CcSEcCtD
Gadopentetate dimeglumine—Tinnitus—Doxorubicin—liver cancer	0.00154	0.00173	CcSEcCtD
Gadopentetate dimeglumine—Cardiac disorder—Doxorubicin—liver cancer	0.00153	0.00172	CcSEcCtD
Gadopentetate dimeglumine—Flushing—Doxorubicin—liver cancer	0.00153	0.00172	CcSEcCtD
Gadopentetate dimeglumine—Tension—Epirubicin—liver cancer	0.00152	0.00172	CcSEcCtD
Gadopentetate dimeglumine—Dysgeusia—Epirubicin—liver cancer	0.00152	0.00171	CcSEcCtD
Gadopentetate dimeglumine—Back pain—Epirubicin—liver cancer	0.0015	0.00169	CcSEcCtD
Gadopentetate dimeglumine—Angiopathy—Doxorubicin—liver cancer	0.0015	0.00169	CcSEcCtD
Gadopentetate dimeglumine—Immune system disorder—Doxorubicin—liver cancer	0.00149	0.00168	CcSEcCtD
Gadopentetate dimeglumine—Mediastinal disorder—Doxorubicin—liver cancer	0.00149	0.00167	CcSEcCtD
Gadopentetate dimeglumine—Chills—Doxorubicin—liver cancer	0.00148	0.00167	CcSEcCtD
Gadopentetate dimeglumine—Arrhythmia—Doxorubicin—liver cancer	0.00147	0.00166	CcSEcCtD
Gadopentetate dimeglumine—Mental disorder—Doxorubicin—liver cancer	0.00145	0.00163	CcSEcCtD
Gadopentetate dimeglumine—Erythema—Doxorubicin—liver cancer	0.00144	0.00162	CcSEcCtD
Gadopentetate dimeglumine—Agitation—Epirubicin—liver cancer	0.00143	0.00161	CcSEcCtD
Gadopentetate dimeglumine—PGD—Metabolism—UGDH—liver cancer	0.00142	0.0148	CbGpPWpGaD
Gadopentetate dimeglumine—Tension—Doxorubicin—liver cancer	0.00141	0.00159	CcSEcCtD
Gadopentetate dimeglumine—Dysgeusia—Doxorubicin—liver cancer	0.00141	0.00158	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Epirubicin—liver cancer	0.0014	0.00158	CcSEcCtD
Gadopentetate dimeglumine—Syncope—Epirubicin—liver cancer	0.00139	0.00157	CcSEcCtD
Gadopentetate dimeglumine—Back pain—Doxorubicin—liver cancer	0.00139	0.00156	CcSEcCtD
Gadopentetate dimeglumine—Loss of consciousness—Epirubicin—liver cancer	0.00137	0.00154	CcSEcCtD
Gadopentetate dimeglumine—Cough—Epirubicin—liver cancer	0.00136	0.00153	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Epirubicin—liver cancer	0.00135	0.00151	CcSEcCtD
Gadopentetate dimeglumine—Hypertension—Epirubicin—liver cancer	0.00134	0.00151	CcSEcCtD
Gadopentetate dimeglumine—PGD—Metabolism—EPT1—liver cancer	0.00133	0.0139	CbGpPWpGaD
Gadopentetate dimeglumine—Chest pain—Epirubicin—liver cancer	0.00132	0.00149	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Epirubicin—liver cancer	0.00132	0.00149	CcSEcCtD
Gadopentetate dimeglumine—Agitation—Doxorubicin—liver cancer	0.00132	0.00149	CcSEcCtD
Gadopentetate dimeglumine—Anxiety—Epirubicin—liver cancer	0.00132	0.00148	CcSEcCtD
Gadopentetate dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00131	0.00148	CcSEcCtD
Gadopentetate dimeglumine—Malaise—Doxorubicin—liver cancer	0.0013	0.00146	CcSEcCtD
Gadopentetate dimeglumine—Dry mouth—Epirubicin—liver cancer	0.00129	0.00146	CcSEcCtD
Gadopentetate dimeglumine—Syncope—Doxorubicin—liver cancer	0.00129	0.00145	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Epirubicin—liver cancer	0.00128	0.00144	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Epirubicin—liver cancer	0.00127	0.00143	CcSEcCtD
Gadopentetate dimeglumine—PGD—Metabolism—TAT—liver cancer	0.00127	0.0132	CbGpPWpGaD
Gadopentetate dimeglumine—Loss of consciousness—Doxorubicin—liver cancer	0.00126	0.00142	CcSEcCtD
Gadopentetate dimeglumine—Cough—Doxorubicin—liver cancer	0.00125	0.00141	CcSEcCtD
Gadopentetate dimeglumine—Shock—Epirubicin—liver cancer	0.00125	0.0014	CcSEcCtD
Gadopentetate dimeglumine—Convulsion—Doxorubicin—liver cancer	0.00125	0.0014	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Epirubicin—liver cancer	0.00124	0.0014	CcSEcCtD
Gadopentetate dimeglumine—Hypertension—Doxorubicin—liver cancer	0.00124	0.0014	CcSEcCtD
Gadopentetate dimeglumine—Tachycardia—Epirubicin—liver cancer	0.00124	0.00139	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Epirubicin—liver cancer	0.00123	0.00139	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Epirubicin—liver cancer	0.00123	0.00138	CcSEcCtD
Gadopentetate dimeglumine—Chest pain—Doxorubicin—liver cancer	0.00122	0.00138	CcSEcCtD
Gadopentetate dimeglumine—Arthralgia—Doxorubicin—liver cancer	0.00122	0.00138	CcSEcCtD
Gadopentetate dimeglumine—Anxiety—Doxorubicin—liver cancer	0.00122	0.00137	CcSEcCtD
Gadopentetate dimeglumine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00122	0.00137	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Epirubicin—liver cancer	0.00121	0.00136	CcSEcCtD
Gadopentetate dimeglumine—Dry mouth—Doxorubicin—liver cancer	0.0012	0.00135	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Epirubicin—liver cancer	0.00118	0.00133	CcSEcCtD
Gadopentetate dimeglumine—Confusional state—Doxorubicin—liver cancer	0.00118	0.00133	CcSEcCtD
Gadopentetate dimeglumine—Anaphylactic shock—Doxorubicin—liver cancer	0.00117	0.00132	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00115	0.0013	CcSEcCtD
Gadopentetate dimeglumine—Shock—Doxorubicin—liver cancer	0.00115	0.0013	CcSEcCtD
Gadopentetate dimeglumine—Nervous system disorder—Doxorubicin—liver cancer	0.00115	0.00129	CcSEcCtD
Gadopentetate dimeglumine—Tachycardia—Doxorubicin—liver cancer	0.00114	0.00129	CcSEcCtD
Gadopentetate dimeglumine—Skin disorder—Doxorubicin—liver cancer	0.00114	0.00128	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Epirubicin—liver cancer	0.00114	0.00128	CcSEcCtD
Gadopentetate dimeglumine—Hyperhidrosis—Doxorubicin—liver cancer	0.00113	0.00128	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Epirubicin—liver cancer	0.00113	0.00127	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Epirubicin—liver cancer	0.00113	0.00127	CcSEcCtD
Gadopentetate dimeglumine—Anorexia—Doxorubicin—liver cancer	0.00112	0.00126	CcSEcCtD
Gadopentetate dimeglumine—Decreased appetite—Epirubicin—liver cancer	0.0011	0.00124	CcSEcCtD
Gadopentetate dimeglumine—Hypotension—Doxorubicin—liver cancer	0.0011	0.00123	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Epirubicin—liver cancer	0.00109	0.00123	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Epirubicin—liver cancer	0.00109	0.00123	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Epirubicin—liver cancer	0.00108	0.00122	CcSEcCtD
Gadopentetate dimeglumine—Pain—Epirubicin—liver cancer	0.00108	0.00122	CcSEcCtD
Gadopentetate dimeglumine—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00107	0.0012	CcSEcCtD
Gadopentetate dimeglumine—Paraesthesia—Doxorubicin—liver cancer	0.00105	0.00119	CcSEcCtD
Gadopentetate dimeglumine—Dyspnoea—Doxorubicin—liver cancer	0.00105	0.00118	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Epirubicin—liver cancer	0.00104	0.00118	CcSEcCtD
Gadopentetate dimeglumine—Somnolence—Doxorubicin—liver cancer	0.00104	0.00117	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Epirubicin—liver cancer	0.00104	0.00117	CcSEcCtD
Gadopentetate dimeglumine—PGD—Disease—LTF—liver cancer	0.00103	0.0107	CbGpPWpGaD
Gadopentetate dimeglumine—Decreased appetite—Doxorubicin—liver cancer	0.00102	0.00115	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00101	0.00114	CcSEcCtD
Gadopentetate dimeglumine—Fatigue—Doxorubicin—liver cancer	0.00101	0.00114	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Epirubicin—liver cancer	0.00101	0.00113	CcSEcCtD
Gadopentetate dimeglumine—Constipation—Doxorubicin—liver cancer	0.001	0.00113	CcSEcCtD
Gadopentetate dimeglumine—Pain—Doxorubicin—liver cancer	0.001	0.00113	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Epirubicin—liver cancer	0.001	0.00113	CcSEcCtD
Gadopentetate dimeglumine—Abdominal pain—Epirubicin—liver cancer	0.001	0.00113	CcSEcCtD
Gadopentetate dimeglumine—Feeling abnormal—Doxorubicin—liver cancer	0.000967	0.00109	CcSEcCtD
Gadopentetate dimeglumine—Gastrointestinal pain—Doxorubicin—liver cancer	0.000959	0.00108	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Epirubicin—liver cancer	0.000934	0.00105	CcSEcCtD
Gadopentetate dimeglumine—Urticaria—Doxorubicin—liver cancer	0.000932	0.00105	CcSEcCtD
Gadopentetate dimeglumine—PGD—NRF2 pathway—TGFB1—liver cancer	0.00093	0.00967	CbGpPWpGaD
Gadopentetate dimeglumine—Abdominal pain—Doxorubicin—liver cancer	0.000927	0.00104	CcSEcCtD
Gadopentetate dimeglumine—Body temperature increased—Doxorubicin—liver cancer	0.000927	0.00104	CcSEcCtD
Gadopentetate dimeglumine—Asthenia—Epirubicin—liver cancer	0.000909	0.00102	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Epirubicin—liver cancer	0.000897	0.00101	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Epirubicin—liver cancer	0.000867	0.000976	CcSEcCtD
Gadopentetate dimeglumine—Hypersensitivity—Doxorubicin—liver cancer	0.000864	0.000972	CcSEcCtD
Gadopentetate dimeglumine—PGD—Metabolism—GLUL—liver cancer	0.00086	0.00894	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—CPT1B—liver cancer	0.00086	0.00894	CbGpPWpGaD
Gadopentetate dimeglumine—Asthenia—Doxorubicin—liver cancer	0.000842	0.000947	CcSEcCtD
Gadopentetate dimeglumine—Dizziness—Epirubicin—liver cancer	0.000838	0.000943	CcSEcCtD
Gadopentetate dimeglumine—Pruritus—Doxorubicin—liver cancer	0.00083	0.000934	CcSEcCtD
Gadopentetate dimeglumine—PGD—Metabolism—NR1H4—liver cancer	0.000829	0.00862	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—GSTA3—liver cancer	0.000815	0.00848	CbGpPWpGaD
Gadopentetate dimeglumine—Vomiting—Epirubicin—liver cancer	0.000806	0.000907	CcSEcCtD
Gadopentetate dimeglumine—Diarrhoea—Doxorubicin—liver cancer	0.000802	0.000903	CcSEcCtD
Gadopentetate dimeglumine—Rash—Epirubicin—liver cancer	0.000799	0.000899	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Epirubicin—liver cancer	0.000798	0.000899	CcSEcCtD
Gadopentetate dimeglumine—Headache—Epirubicin—liver cancer	0.000794	0.000894	CcSEcCtD
Gadopentetate dimeglumine—PGD—Disease—ALDOB—liver cancer	0.000793	0.00825	CbGpPWpGaD
Gadopentetate dimeglumine—Dizziness—Doxorubicin—liver cancer	0.000776	0.000873	CcSEcCtD
Gadopentetate dimeglumine—Nausea—Epirubicin—liver cancer	0.000753	0.000847	CcSEcCtD
Gadopentetate dimeglumine—Vomiting—Doxorubicin—liver cancer	0.000746	0.000839	CcSEcCtD
Gadopentetate dimeglumine—PGD—Metabolism—GSTA4—liver cancer	0.000746	0.00775	CbGpPWpGaD
Gadopentetate dimeglumine—Rash—Doxorubicin—liver cancer	0.00074	0.000832	CcSEcCtD
Gadopentetate dimeglumine—Dermatitis—Doxorubicin—liver cancer	0.000739	0.000831	CcSEcCtD
Gadopentetate dimeglumine—Headache—Doxorubicin—liver cancer	0.000735	0.000827	CcSEcCtD
Gadopentetate dimeglumine—PGD—Metabolism—GSTA2—liver cancer	0.000727	0.00756	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—GSTA1—liver cancer	0.000701	0.00729	CbGpPWpGaD
Gadopentetate dimeglumine—Nausea—Doxorubicin—liver cancer	0.000697	0.000784	CcSEcCtD
Gadopentetate dimeglumine—PGD—Metabolism—NAT2—liver cancer	0.000693	0.00721	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—ALDOB—liver cancer	0.000665	0.00691	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—CRABP1—liver cancer	0.000634	0.00659	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—ADAM17—liver cancer	0.000627	0.00652	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—PSMD10—liver cancer	0.00059	0.00613	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—PSMA4—liver cancer	0.00059	0.00613	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—GOT2—liver cancer	0.000574	0.00597	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—HPGDS—liver cancer	0.000554	0.00576	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—GOT1—liver cancer	0.000495	0.00515	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—PSMA4—liver cancer	0.000494	0.00514	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—PSMD10—liver cancer	0.000494	0.00514	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—GOT2—liver cancer	0.00048	0.005	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—PRKCE—liver cancer	0.000457	0.00475	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—CYP2E1—liver cancer	0.000452	0.0047	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—CYCS—liver cancer	0.000423	0.0044	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—GGT1—liver cancer	0.000415	0.00431	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—GOT1—liver cancer	0.000415	0.00431	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—H2AFX—liver cancer	0.000398	0.00414	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—GSTP1—liver cancer	0.000373	0.00387	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—HMOX1—liver cancer	0.000367	0.00382	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—MTHFR—liver cancer	0.000361	0.00376	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—TERT—liver cancer	0.00036	0.00375	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—GSTM1—liver cancer	0.000342	0.00356	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—CYP1A1—liver cancer	0.000325	0.00338	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—APC—liver cancer	0.000304	0.00316	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—MTHFR—liver cancer	0.000303	0.00315	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—PPARA—liver cancer	0.000297	0.00309	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—BRAF—liver cancer	0.000285	0.00297	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—PIK3CD—liver cancer	0.000267	0.00278	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—SERPINE1—liver cancer	0.000264	0.00274	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—PIK3CG—liver cancer	0.000254	0.00264	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—PPARG—liver cancer	0.000245	0.00255	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—RAF1—liver cancer	0.000238	0.00248	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—MTOR—liver cancer	0.000233	0.00242	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—PIK3CB—liver cancer	0.000233	0.00242	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—PIK3CD—liver cancer	0.000223	0.00232	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—ALB—liver cancer	0.000221	0.00229	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—CDKN1B—liver cancer	0.000218	0.00227	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—CTNNB1—liver cancer	0.000206	0.00214	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—CDKN1A—liver cancer	0.000201	0.00209	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—PIK3CB—liver cancer	0.000195	0.00203	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—STAT3—liver cancer	0.00018	0.00187	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—MYC—liver cancer	0.000167	0.00174	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—TGFB1—liver cancer	0.000167	0.00173	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—KRAS—liver cancer	0.000154	0.00161	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—PIK3CA—liver cancer	0.000142	0.00147	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—HRAS—liver cancer	0.000131	0.00136	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—IL6—liver cancer	0.000126	0.00131	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—PIK3CA—liver cancer	0.000119	0.00123	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Disease—AKT1—liver cancer	0.000116	0.0012	CbGpPWpGaD
Gadopentetate dimeglumine—PGD—Metabolism—AKT1—liver cancer	9.7e-05	0.00101	CbGpPWpGaD
